GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2009

Cellectis to Employ Diatos’ Drug Delivery Platform

  • Cellectis acquired the Vectocell® intracellular delivery technology from Diatos to optimize the efficacy of its drug candidates. This platform reportedly improves the performance of a therapeutic compound by enabling specific entry into the target cell compartment or organ in animals and humans.

    It is based on the fusion between the therapeutic protein and an antibody-derived peptide that facilitates passive entry into the cell. Experimental data shows that this targeting technique provokes minimal immunogenicity and thus reportedly offers excellent safety.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?